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Idiopathic pulmonary fibrosis (IPF) affects lung parenchyma with progressing fibrosis. 
In this study, we aimed to replicate MUC5B rs35705950 variants and determine new 
plausible candidate variants for IPF among four different European populations. We 
genotyped 26 IPF candidate loci in 165 IPF patients from four European countries, such 
as Czech Republic (n = 41), Germany (n = 33), Greece (n = 40), France (n = 51), and 
performed association study comparing observed variant distribution with that obtained 
in a genetically similar Czech healthy control population (n = 96) described in our earlier 
data report. A highly significant association for a promoter variant (rs35705950) of mucin 
encoding MUC5B gene was observed in all IPF populations, individually and combined 
[odds ratio (95% confidence interval); p-value as 5.23 (8.94–3.06); 1.80 × 10−11]. Another 
non-coding variant, rs7934606 in MUC2 was significant among German patients 
[2.85 (5.05–1.60); 4.03 × 10−4] and combined European IPF cases [2.18 (3.16–1.50); 
3.73 × 10−5]. The network analysis for these variants indicated gene–gene and gene–
phenotype interactions in IPF and lung biology. With replication of MUC5B rs35705950 
previously reported in U.S. populations of European descent and indicating other plausi-
ble polymorphic variants relevant for IPF, we provide additional reference information for 
future extended functional and population studies aimed, ideally with inclusion of clinical 
parameters, at identification of IPF genetic markers.
Keywords: MUC5B, MUC2, cytokines, idiopathic pulmonary fibrosis, sequenom MassarraY, single nucleotide 
polymorphism, association study, network analysis
inTrODUcTiOn
Idiopathic pulmonary fibrosis (IPF) is a chronic, progressive form of fibrosing interstitial pneumonia 
of unknown cause that predominantly affects lung parenchyma, leading to progressive worsening 
of dyspnea and lung function (1). In pathobiological mechanisms of IPF, role for gene variation has 
been implicated and spectrum of susceptible/protective polymorphic gene variants, including those 
TaBle 1 | subjects characteristics under study comprising iPF cases from four different populations.
control subjectsa european iPF cases
czech german greek French Total iPF
N 96 41 33 40 51 165
Age, mean ± SD 34.45 ± 8.94 59.78 ± 10.12 66.25 ± 12.28 72.15 ± 7.71 72.19 ± 11.97 67.97 ± 11.60
Age, range 18–57 42–81 36–85 51–88 36–92 36–92
Males:females 45:51 23:18 26:7 32:8 44:7 125:40
aHealthy control subjects from our previous data report (15).
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in loci governing immune and inflammatory reactions and sign-
aling processes, has been recently reported from genome-wide 
association studies (GWAS) or population-based case–control 
investigations (2–13); notably distribution of nominated gene 
variants varied among populations of different ancestry (Table S1 
in Supplementary Material). Further, recent bioinformatics 
approaches yielded a genomic model that accurately predicted 
high- and low-risk IPF patients using a list of 118 IPF prognostic 
predictor genes, many of those with immune-, also T-cell-related 
functions (14). In aggregate, these reports implicated involvement 
of multiple genetic factors in IPF development and emphasized 
the need for their evaluation in different populations to decipher 
the plausible pathobiological mechanism of IPF.
In context of the above efforts, we have recently identified and 
reported 26 IPF-associated candidate loci (15). Besides charac-
terizing their major functions, e.g., in regulating production of 
mucins (MUC5B and MUC2) or of pro-inflammatory cytokines 
(IL-1, IL-8) and also in cell signaling and innate immunity pro-
cesses (TLR3 and TOLLIP) involved in inflammatory and profi-
brotic pathways (http://www.ncbi.nlm.nih.gov/pmc/articles/
PMC4585032/table/T1/), we have described the approach for 
their simultaneous investigation using a novel mass spectrometry 
based matrix-assisted laser desorption/ionization time-of-flight 
(MALDI-TOF) multiplexed genotyping assay and reported their 
gene frequencies in healthy Czech (European) population (15). 
There, we also suggested the wider application of the data from 
this report for association studies among genetically homogenous 
populations following the recommendation of STrengthening 
the REporting of Genetic Association studies (STREGA) (16). 
Suggestion to include this particular control population in the 
present IPF association study in different European populations 
was based on reports of genetic similarity among Europeans, for 
example from results of genotyping 6000 individuals as control 
samples for >300,000 single nucleotide polymorphisms (SNPs) 
in a GWAS (17) and findings of a HapMap study (18). Further, 
in our decision we also reflected recommendations of HLA-NET 
network group for usage of geographical and/or cultural criteria 
to describe human populations (19) and also our own observa-
tions of substantial degree of homogeneity in distribution of 
immune-related gene variants within European populations, 
including Greeks (20).
Hereby, we report the results from a multicenter association 
gene study in which we determined the status (genotype distribu-
tion, genotype, and allele frequencies with carriage rate) of 26 
IPF candidate loci. Here, we have performed a comparative study 
for association of these IPF candidate genetic variants among 
four different European (Czech, German, Greek, and French) 
populations and have ammended it by network prediction for 
gene–gene/gene–phenotype interactions in IPF and lung biology. 
We suggest that future extended and replicative studies following 
hereby described approach could enable better understanding of 
IPF pathogenesis, and if further supported by patient laboratory 
and clinical data, it could help to nominate novel disease markers.
MaTerials anD MeThODs
characteristics of iPF cases
In this study, 165 IPF patients from four European populations 
comprising 41 Czechs (Centre: University Hospital, Olomouc), 
33 Germans (University Medical Center, Freiburg), 40 Greeks 
(Medical School University, Athens), and 51 French (University 
Hospital, Paris), representing Central, Southern, and Western 
Europe, were enrolled (Table 1).
All subjects were unrelated, white, and of European origin 
living in specified countries of Europe and speaking their respec-
tive national languages. The IPF cases were diagnosed as per 
ATS/ERS/JRS/ALAT guidelines (1, 21, 22) with typical clinical 
features and abnormalities on chest high-resolution computed 
tomography (HRCT) scans, abnormal lung function tests with 
reduced diffusing capacity of the lung for CO (DLCO), and/or 
restrictive pulmonary deficit, exclusion of other known causes 
of interstitial lung disease (ILD). For comparisons of genotype, 
allele frequency, and carriage rate (phenotype frequency) of 
analyzed genomic variants and case–control association study, 
we have utilized the data on distribution of these variants in 96 
Czech healthy controls (15). Genomic DNA was isolated from 
peripheral blood leukocytes by standard salting out method 
(23). Informed consent was obtained from all study participants. 
The study was performed with approval of institutional ethical 
committees at respective centers (Ethics Commitee of University 
Hospital and Medical Faculty of Palacky University, Olomouc, 
Czech Republic; Ethics Committee of the University Hospital 
Freiburg, Germany; Ethics Committee Hospital for Diseases of 
the Chest, Athens, Greece; and Comité Consultatif de protection 
des Personnes dans la recherche biomédicale-hôpital Robert 
Ballanger, France).
assay Design, Pcr amplification  
and genotyping
The details of the panel comprising 26 IPF candidate loci 
and genotyping procedure in IPF cases have been described 
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previously (15). In brief, a total of 26 SNPs reported as associated 
with IPF in literature were selected. These SNPs were located 
within the genes of different functional categories (mucus produc-
tion, pro-inflammatory cytokines, chemokines, innate immune 
response, telomerase maintenance, cell surface remodeling, 
GTPase activator activity, cell-cycle regulators, phospholipid 
translocators, desmoplakin production, etc.). For PCR ampli-
fication and single base extension (SBE) reaction, the primer 
pairs along with extension primers were designed using Assay 
design suite v2.0. These primers were multiplexed and genotyped 
using Sequenom MassARRAY platform integrating iPLEX® 
SBE reaction and MassARRAY® technology (Agena Bioscience, 
San Diego, CA, USA) based MALDI-TOF MS assay. The assay 
consists of an initial locus-specific PCR amplification followed 
by SBE using mass-modified dideoxynucleotide terminators of 
an oligonucleotide primer that anneals immediately upstream of 
the target polymorphic site. The distinct mass of extended primer 
traces the alternative alleles using MassARRAY Typer 4.0.20. 
For quality control (QC) step, we determined data missing rate 
per individuals and missing rate per SNP. Also, for QC of SNP 
genotyping, positive and negative template control samples were 
included in each assay plate. Any assay found as positive in nega-
tive template control were removed from the study.
statistical analysis
Each SNP was tested for Hardy–Weinberg equilibrium (HWE) by 
Pearson’s Chi-square (χ2) test or Fisher exact test, as applicable. 
SNPs within HWE (p > 0.05) and sufficiently common [minor 
allele frequency (MAF) > 5%] in studied population were included. 
Carriage rate (phenotype frequency) was calculated as number of 
individuals carrying one (or two) copies of a particular allele on 
one or both (maternal and paternal) chromosomes. Association 
of SNPs minor alleles with IPF susceptibility were evaluated by 
Fisher’s exact test providing odds ratio (OR), 95% confidence 
interval (CI), and level of significance (p). For Bonferroni cor-
rection of multiple comparison (number of test = 100; 20 SNPs 
for four individual and the combined populations), a stringent 
approach with p-value < 0.05/100 (5 × 10−4) was considered as 
significant.
network analysis
Prediction of gene–gene network for plausible candidate variants 
(p < 0.05) and their interaction with IPF and other phenotypes, 
such as lung disease, lung injury, and lung function was performed 
using Phenolyzer, a tool for phenotype-based prioritization of 
candidate genes in human diseases (24). The candidate genes and 
their relationship with IPF and related phenotypes were investi-
gated in several databases to determine and score relevant seed 
genes. The seed genes are then expanded to include related genes, 
on the basis of several types of gene–gene relationship compo-
nents, such as exhibiting a protein–protein interaction, sharing a 
gene family or biological pathway, or transcriptionally regulating 
or being regulated by another gene. Finally, these different types 
of scores from seed gene ranking and gene–gene relationships are 
integrated to generate a ranked candidate gene list, together with 
gene–gene and gene–phenotypes interactions used to normalize 
the scores in range 0–1 (24).
resUlTs
The characteristics of IPF patients and healthy control subjects 
included in this study are presented in Table 1. The proportions 
of IPF male cases were higher than of female cases. Following QC 
steps for missing rates, the genotyping data from all individual 
passed the QC with (i) missing frequency per individual 0.038 
(N_MISS = 1) to 0.077 (N_MISS = 2) (a single IPF case from 
Greek population that failed the assay was not included in this 
study), and (ii) genotype missing frequency (F_MISS/assay error 
rate; Table 2) 0.004 to 0.015. Five SNPs showed departure from 
HWE (Table S2 in Supplementary Material), namely, PRKCE 
rs628877 (p = 0.02 in combined IPF cases with F_MISS = 0.008), 
IL-4 rs2243250 (p =  0.01, F_MISS =  0.0146 in Czech IPF and 
p =  1.2 ×  10−4, F_MISS =  0.011 in combined IPF cases), IL-4 
rs2070874 (p = 0.02, F_MISS = 0 in Czech IPF), IL-4Rα rs1801275 
(p =  0.04, F_MISS =  0 in Czech healthy controls; p =  0.03, 
F_MISS = 0 in Greek IPF and p = 0.01, F_MISS = 0 in combined 
IPF cases), and MAPT rs1981997 (p = 0.03, F_MISS = 0.007 in 
French IPF cases). Further, with MAF threshold check, TP53 
rs12951053 was found with MAF = 0.04, F_MISS = 0 in Greek 
IPF cases. Thus, keeping the QC stringent conditions, these six 
SNPs were removed from further analysis, for which 20 variants 
remained (Table 2).
The primary analysis (p < 0.05) using allelic (multiplicative) 
genetic model revealed a total of nine SNPs for IPF susceptibility. 
Among these, three SNPs were shared among different IPF popu-
lations: first, rs35705950*T within promoter region of Mucin5B 
(MUC5B) was highly significant among all the IPF popula-
tions  –  Czech [OR (95% CI); p: 3.77 (7.47–1.9); 1.62 ×  10−4]; 
German [4.83 (9.79–2.39); 1.55 × 10−5]; Greek [5.46 (10.82–2.76); 
1.13 × 10−6]; French [6.77 (12.65–3.62); 5.28 × 10−10]; and com-
bined IPF cases [5.23 (8.94–3.06); 1.80 × 10−11] (Table 2). Second, 
rs7934606*A within intron region of Mucin2 (MUC2) was sig-
nificant for German [2.85 (5.05–1.60); 4.03 × 10−4], Greek [2.45 
(4.19–1.43); 1.43 × 10−3], French [2.36 (3.86–1.44); 7.03 × 10−4], 
and combined IPF [2.18 (3.16–1.50); 3.73 × 10−5] cases. The third 
variant, rs1799899*A located in exon region of Transferrin (TF) 
gene was significant for Germans [2.89 (6.47–1.30); 1.12 × 10−2], 
French [2.20 (4.65–1.04); 4.58  ×  10−2], and in combined IPF 
[2.06 (3.78–1.12); 1.87 × 10−2] cases. Prediction of loss-/gain-of-
function for functional variant TF rs1799899 suggested it as a 
probably damaging mutation (Polyphen score: 0.869 and SIFT 
score: 0.07).
The other six significant SNPs were featured in individual 
populations of which three were associated with IPF in Czech: 
(i) rs12602273*G in Tumor protein 53 (TP53) [2.43 (5.3–1.11); 
3.10 × 10−2]; (ii) rs4277405*C in Angiotensin converting enzyme 
(ACE) [0.54 (0.96–0.30); 3.71  ×  10−2]; and (iii) rs4459609*C 
in ACE [0.54 (0.96–0.30); 3.71 ×  10−2] and one each in Greek: 
Telomerase reverse transcriptase (TERT) rs2736100*G [0.49 
(0.83–0.29); 1.12 ×  10−2]; French: ATPase, type 11A (ATP11A) 
rs1278769*A [0.51 (0.92–0.28); 2.51 ×  10−2]; and in total IPF 
cases: Interleukin-1 α (IL-1α) rs1800587*T [0.68 (0.99–0.46); 
4.94 × 10−2] (Table 2).
These findings of allelic model were in concordance with 
Pearson’s χ2 test and additive test of logistic regression analysis 
TaBle 2 | allelic model of association for iPF risk among four european populations.
s. 
no.
gene snP Minor 
allele
czechs germans greeks French Total assay error  
rate
Or (95% ci) p Or (95% ci) p Or (95% ci) p Or (95% ci) p Or (95% ci) p
1 IL-1α rs1800587 T 0.65 (1.16–0.37) 0.16 0.78 (1.42–0.42) 0.45 0.56 (1.01–0.31) 0.06 0.74 (1.25–0.44) 0.30 0.68 (0.99–0.46) 4.94 × 10−2 0
2 L-1β rs16944 A 1.15 (1.98–0.67) 0.67 0.79 (1.46–0.42) 0.54 1.01 (1.76–0.58) 1.00 1.14 (1.9–0.69) 0.61 1.03 (1.51–0.71) 0.92 0
3 IL-1β rs1143634 T 1.06 (1.93–0.59) 0.88 1.34 (2.49–0.72) 0.42 0.71 (1.37–0.37) 0.34 1.06 (1.84–0.61) 0.89 1.02 (1.54–0.68) 1.00 0
4 LRRC34 rs6793295 C 0.87 (1.55–0.49) 0.66 0.96 (1.77–0.52) 1.00 0.79 (1.43–0.44) 0.46 1.35 (2.24–0.81) 0.29 1.00 (1.48–0.68) 1.00 0
5 TF rs1799899 A 1.46 (3.47–0.61) 0.48 2.89 (6.47–1.3) 1.12 × 10−2 1.88 (4.3–0.82) 0.17 2.20 (4.65–1.04) 4.58 × 10−2 2.06 (3.78–1.12) 1.87 × 10−2 0
6 IL-8 rs4073 A 1.28 (2.14–0.76) 0.36 1.16 (2.03–0.66) 0.67 1.16 (1.95–0.69) 0.60 1.11 (1.8–0.69) 0.71 1.17 (1.67–0.82) 0.41 0
7 FAM13A rs2609255 G 1.01 (1.82–0.56) 1.00 0.79 (1.54–0.4) 0.51 1.04 (1.88–0.57) 0.88 1.46 (2.47–0.86) 0.17 1.09 (1.64–0.73) 0.68 0
8 TLR3 rs3775291 A 0.94 (1.62–0.54) 0.89 0.61 (1.16–0.32) 0.17 0.72 (1.29–0.41) 0.32 0.72 (1.22–0.43) 0.24 0.75 (1.1–0.51) 0.14 0
9 TERT rs2736100 G 1.01 (1.70–0.60) 1.00 0.85 (1.51–0.48) 0.67 0.49 (0.83–0.29) 1.12 × 10−2 1.23 (1.99–0.76) 0.46 1.23 (1.76–0.86) 0.28 0
10 IL-13 rs1800925 T 0.66 (1.22–0.35) 0.23 0.65 (1.27–0.34) 0.26 1.08 (1.91–0.61) 0.88 0.83 (1.43–0.48) 0.59 0.80 (1.2–0.54) 0.30 0.008
11 IL-4 rs2243248 G 0.47 (1.69–0.13) 0.29 0.59 (2.13–0.16) 0.57 1.78 (4.19–0.75) 0.24 1.20 (2.88–0.5) 0.66 1.02 (2.01–0.52) 1.00 0.008
12 CDNK1A rs733590 C 1.21 (2.05–0.72) 0.50 0.76 (1.38–0.42) 0.46 1.15 (1.95–0.67) 0.68 1.01 (1.65–0.62) 1.00 1.03 (1.49–0.72) 0.93 0
13 OBFC1 rs11191865 A 1.67 (2.81–0.99) 0.06 1.75 (3.07–0.99) 0.06 1.07 (1.8–0.63) 0.89 1.43 (2.31–0.88) 0.18 1.44 (2.06–1.01) 0.06 0
14 MUC2 rs7934606 A 1.41 (2.41–0.83) 0.21 2.85 (5.05–1.60) 4.03 × 10−4 2.45 (4.19–1.43) 1.43 × 10−3 2.36 (3.86–1.44) 7.03 × 10−4 2.18 (3.16–1.50) 3.73 × 10−5 0.004
15 MUC5B rs35705950 T 3.77 (7.47–1.9) 1.62 × 10−4 4.83 (9.79–2.39) 1.55 × 10−5 5.46 (10.82–2.76) 1.13 × 10−6 6.77 (12.65–3.62) 5.28 × 10−10 5.23 (8.94–3.06) 1.80 × 10−11 0.015
16 ATP11A rs1278769 A 1.10 (1.92–0.63) 0.77 0.53 (1.06–0.26) 0.08 1.02 (1.79–0.57) 1.00 0.51 (0.92–0.28) 2.51 × 10−2 0.76 (1.13–0.51) 0.18 0
17 TP53 rs12602273 G 2.43 (5.3–1.11) 3.10 × 10−2 1.40 (3.6–0.54) 0.45 1.13 (2.89–0.44) 0.81 1.57 (3.5–0.71) 0.29 1.63 (3.03–0.87) 0.14 0
18 ACE rs4277405 C 0.54 (0.96–0.30) 3.71 × 10−2 1.08 (1.92–0.61) 0.88 1.11 (1.9–0.65) 0.78 1.12 (1.83–0.68) 0.71 0.94 (1.36–0.65) 0.78 0
19 ACE rs4459609 C 0.54 (0.96–0.30) 3.71 × 10−2 1.08 (1.92–0.61) 0.88 1.11 (1.9–0.65) 0.78 1.08 (1.76–0.66) 0.80 0.93 (1.34–0.64) 0.71 0
20 DPP9 rs12610495 G 1.01 (1.82–0.56) 1.00 1.56 (2.85–0.86) 0.15 1.01 (1.84–0.55) 1.00 1.14 (1.96–0.66) 0.68 1.15 (1.72–0.77) 0.54 0.008
Bold values are significant with Bonferroni corrected p < 5 × 10−4.
OR: Odds ratio; CI: Confidence interval.
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FigUre 1 | network of genes with candidate loci and their interaction with iPF, lung injury, lung function, and lung disease phenotypes (ilD, 
interstitial lung disease; cWP, coal worker’s pneumoconiosis; cOPD, chronic obstructive pulmonary disease; DPB, diffuse panbronchiolitis; nsclc, 
non-small cell lung cancer; sclc, small cell lung cancer; Ph, pulmonary hypertension).
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with similar panel and population distribution/stratification 
of significant risk variants, and an exceptional addition of 
rs11191865*A (p  =  0.046) in Oligonucleotide/oligosaccharide-
binding fold containing 1 (OBFC1) exclusively in total IPF set 
under χ2 test.
Network analysis among genes with significant variants 
showed MUC5B and MUC2 in same gene family (Figure S1 in 
Supplementary Material), transcriptional interaction among 
MUC2 and TP53 (Figure S2 in Supplementary Material), and all 
identified candidate genes belonged to the same biosystem (Figure 
S3 in Supplementary Material). Further prediction based on their 
records in several databases (CLINVAR, ORPHANET, OMIM, 
DISGENET, GWAS, HTRI, GENE_FAMILY, and BIOSYSTEM), 
gene–gene interaction and interaction with phenotypes (IPF, lung 
disease, lung injury, and lung function) has (Figure 1) prioritized 
MUC5B as highest-ranked genes and indicated MUC5B, TERT, 
and ATP11a as seed genes, while TP53, IL1A, MUC2, ACE, and TF 
as predictive genes based on their normalized scores (Figure 2).
Applying rather conservative Bonferroni correction for 
multiple comparisons (100 tests, see Materials and Methods), 
MUC5B rs35705950*T remained as highly significant in all IPF 
populations, Czech (p =  1.62 ×  10−4), German (1.55 ×  10−5), 
Greek (1.13 ×  10−6), French (5.28 ×  10−10), and in combined 
IPF population (1.80  ×  10−11); whereas MUC2 rs7934606*A 
was significant in German (4.03 ×  10−4) and in combined IPF 
(3.73 × 10−5) (Table 2). The inheritance hypothesis for Bonferroni 
significant variants, MUC5B rs35705950 and MUC2 rs7934606, 
under allelic model for IPF association were also tested for other 
models and the variant rs35705950 was found in concordance 
to the dominant model indicating allele T for increased risk 
(Table 3).
For the highly significant variants, we also report the allele fre-
quency of rs35705950*T risk allele to range from 0.09 to 0.41 and 
rs7934606*A from 0.32 to 0.58 among the analyzed four European 
populations (Table S2 in Supplementary Material). Among IPF 
cases, the allele frequency and carriage rate for rs35705950*T 
were lowest in Czech (0.28 and 0.49, respectively) and highest in 
French (0.41 and 0.65, respectively); while rs7934606*A has low-
est frequencies in Czech (0.40 and 0.63, respectively) and highest 
in Germans (0.58 and 0.91, respectively).
DiscUssiOn
This study is a first report of comparative distribution of genotypes 
and alleles of 26 candidate gene variants implicated in mucin 
production, cell-cycle regulation, pro-inflammatory, and profi-
brotic signaling pathways pertinent to IPF pathobiology among 
patients from four populations across Europe (Czech, German, 
Greek, and French). Employing stringent statistical approach 
(p <  5 ×  10−4), we report a high association between MUC5B 
rs35705950*T and IPF susceptibility in all the four analyzed 
populations among Czechs: [OR (95% CI) p] 3.77 (7.47–1.9) 
TaBle 3 | Dominant model of inheritance for highly significant iPF susceptible risk variants with Bonferroni correction among the four european 
populations.
genetic variants czech german greek French Total iPF
Or (95% ci); p Or (95% ci); p Or (95% ci); p Or (95% ci); p Or (95% ci); p
MUC5B rs35705950*T 
(GT + TT vs. GG)
4.76 (2.11–10.75); 
2.21 × 10−4
8.75 (3.59–21.30); 
9.04 × 10−7
6.25 (2.67–14.60); 
1.97 × 10−5
9.167 (4.18–20.12); 
9.6 × 10−9
7.01 (3.77–13.06); 
6.21 × 10−11
MUC2 rs7934606*A 
(GA + AA vs. GG)
1.29 (0.61–2.74); NS 7.45 (2.13–26.12); 
2.73 × 10−4
2.48 (1.06–5.80); 
4.83 × 10−2
2.71 (1.24–5.92); 
1.16 × 10−2
2.47 (1.43–4.26); 
1.27 × 10−3
Bold values are significant with Bonferroni corrected p < 5 × 10−4.
OR, Odds ratio; CI, Confidence interval; NS, Non-significant.
FigUre 2 | Bar plot of seed genes (MUC5B, TERT, and ATP11a) and predicted genes (TP53, IL1A, MUC2, ACE, and TF) normalized scores based on 
the gene–gene and gene–phenotype interactions.
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1.62  ×  10−4, Germans: 4.83 (9.79–2.39) 1.55  ×  10−5, Greeks: 
5.46 (10.82–2.76) 1.13  ×  10−6, and French: 6.77 (12.65–3.62) 
5.28 × 10−10 along with all patients from this study as a whole: 
5.23 (8.94–3.06) 1.80 × 10−11. Thus, we replicate previous find-
ings and provide an insight for predominant association of gel-
forming mucin-encoding gene variants with IPF in Europeans 
and populations of European descent. The role of mucin variants 
was also supported with high significance of MUC2 rs7934606 
among Germans [2.85 (5.05–1.60); 4.03 × 10−4] and combined 
European IPF cases [2.18 (3.16–1.50); 3.73 × 10−5]. The identi-
fied nine variants among MUC5B, MUC2, TF, TP53, ACE, TERT, 
ATP11A, and IL-1α (significant at p < 0.05) were interactive at 
gene–gene and gene–phenotype level in network analysis. The 
present study for inter-population comparison is imperative with 
respect of comparing the distributions of plausible IPF-associated 
gene variants and, thus, may provide starting point(s) for further 
investigations of biological (functional implication of nominated 
loci) and translational (relationship with laboratory/clinical 
parameters) aspects.
Among mucin gene cluster (MUC6, MUC2, MUC5AC, and 
MUC5B) on chromosome 11q15.5, MUC5B is the most pre-
dominant in the normal distal airway epithelium and is widely 
associated with sporadic IPF and familial interstitial pneumonia 
(9, 25–27). The MUC5B promoter-variant rs35705950 SNP pre-
dicted change in transcription factors binding sites (disruption 
of E2F and creation of HOX9 and PAX2) and the risk T-allele has 
been strongly associated with increased MUC5B expression in 
the lung tissue. The relative high frequency of rs35705950*T risk 
allele (IPF cases: 0.28–0.41 and healthy controls: 0.09) observed 
in this study are in concordance with several reports, including 
populations of European descent (Table S1 in Supplementary 
Material). To explain the mucin-expressing structures in IPF 
pathogenesis, Seibold et al. analyzed ciliated, basal, and alveolar 
type II cells in lung tissue and reported predominant expression 
of MUC5B in pseudostratified mucociliary epithelium comprised 
of basal epithelial cells and mucus cells in distal airway. Further, 
it is suggested that mucociliary dysfunction in the distal airway 
causing honeycomb cyst may play a role in the development of 
progressive fibroproliferative lung disease (25, 27). Although 
rs35705950 is reported as highly associated with IPF in Europeans 
and in populations of European descent, interestingly, it is weakly 
associated in East-Asians, such as Chinese, Japanese, and Koreans 
(Table S1 in Supplementary Material). Another mutation in 
the same gene family (Figure S1 in Supplementary Material) 
identified MUC2 rs79834606 as significantly associated in IPF 
(p = 3.8 × 10−6) with MAF (A-allele) 0.54 in IPF cases and 0.41 
in controls (9), which is in accordance to our present findings 
(IPF: 0.40–0.58 and controls: 0.32) (Table S2 in Supplementary 
Material). Similarly, MAF of 0.52 for rs79834606*A was reported 
among IPF cases in a GWAS (3).
Here, we newly identified rs1799899 located in the TF gene as 
IPF risk variant in Germans, French, and in combined European 
IPF cases, significant at primary analysis (0.05 > p > 5 × 10−4). The 
SNP rs1799899 marks a Gly/Ser change located in TF gene encod-
ing a glycoprotein involved in iron ion transport and removal of 
certain organic matter and allergens from serum. As this is the 
first implication of TF gene in context of IPF, in parallel to the 
studies of its possible functional role, this association requires 
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replication (16). The other six IPF risk variants identified in this 
study were featured among individual populations (Table  2). 
Among Czech IPF cases, (i) SNP rs12602273 located in intron of 
TP53 that regulates cell-cycle arrest; while, (ii) rs4277405 and (iii) 
rs4459609 located in promoter region of ACE-II suggested with 
critical profibrotic role in IPF (28, 29) were observed. The MAF 
of rs12602273*G reported as 0.07 in IPF case and 0.08 in healthy 
population of the Netherlands (11) was comparable to our cur-
rent findings (IPF: 0.09–0.12 and controls: 0.08). For Greek IPF 
cases, (iv) a common variant rs2736100 within intron of TERT 
and (v) rs1278769 in 3′-UTR of ATP11A were significant. Several 
studies have reported the telomerase gene mutation causing 
short telomerase as risk factor and poor survival in IPF (2, 30, 
31). These variants, rs2736100*G and rs1278769*A, were initially 
reported in a GWAS study for IPF cases with MAF of 0.43 and 
0.20, respectively (MAF = 0.41–0.63 and 0.18–0.30, respectively 
in this study) (3). Besides, (vi) rs1800587 in 5′-flanking region 
of pro-inflammatory cytokine IL-1α was lesser significant among 
the combined IPF cases. Earlier, a study in Czech population 
has reported rs1800587*T MAF of 0.30 in IPF cases and 0.32 in 
healthy controls (4), similar to our current finding (IPF: 0.27–0.29 
and controls: 0.36).
While MUC5B rs35705950 is highly replicable, the other prob-
able candidate variants (including new report of TF rs1799899 in 
IPF) reported in this study must be replicated in accordance to 
the guidelines for conductance of genetic association studies (16), 
by other independent studies. However, already at this stage, our 
analysis of the gene–gene and gene–phenotype interaction net-
works suggests that these candidate variant genes are pertinent to 
IPF and lung function biology (Figure 1) and provides support 
for biological plausibility of observed variants.
Apart from using Czech population control data for compari-
sons within the European context, which was noted and reasoned 
for in the Section “Introduction,” another limitation of this study 
is that a single national center was included for each of four 
European populations, where a relatively small number of IPF 
cases were genotyped, which reduces the power of our present 
findings. However, with a conservative incidence range of 3–9 
cases per 100,000 per year for Europe (32), the enrolled sample 
size (165 IPF cases) in the present study considerably represents 
the disease among Europeans; moreover, it is comparable with 
sizes of other reported studies (Table S1 in Supplementary 
Material). Off note, our primary aim was to report our findings 
of the candidate IPF genetic variants so that these could be repli-
cated in other centers (16) and investigated further. In this regard, 
investigations of relationships with clinical parameters such as 
lung functions will follow.
Our findings provide evidence that gene variants involved 
in mucin production (MUC5B and MUC2) do increase IPF risk 
among the four European populations, two of which (Czech 
and Greek) have not been studied before in this regard at all. 
Additionally, the nominated variants in TF and other variants 
of TP53, ACE, TERT, ATP11A, and IL-1α may also contribute 
to IPF susceptibility. Despite our panel of 26 gene variants was 
designed across pertinent pathobiological pathways, it did not 
include others from the wide range of plausible IPF-associated 
SNPs regulating immune and fibrotic functions, such as master 
 regulator TGF-β, TNF-α, full spectrum of TLRs, MHC (HLA) 
variants, and also SNPs in regulatory microRNAs (miRNAs) (4, 
8, 33, 34). Therefore, these variants should be prioritized in the 
future studies aimed at extending a profile general and popula-
tion-specific IPF gene biomarkers, including exploration of their 
functions, so that our view on the role of gene variation in origin 
of IPF and its further development more closely approaches the 
reality.
cOnclUsiOn
The present study confirms and further extends strong association 
of MUC5B promoter region variant (rs35705950) with IPF disease 
among Europeans. In addition, it suggests further IPF-associated 
polymorphisms: MUC2 (rs79834606) and TF (rs1799899) variants 
in general, and the other six (TP53 rs12602273, ACE-II rs4277405, 
ACE-II rs4459609, TERT rs2736100, ATP11A rs1278769, and IL-
1α rs1800587) in individual European populations. Their further 
investigation for disease association among extended patient 
cohorts is, therefore, warranted. At the same time, findings of 
our present study represent reference information to be utilized 
for future extended functional and population studies as well as 
for translational research of the nominated variants aiming at 
characterization of biomarkers and/or novel therapeutic targets.
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